Verastem | VSTM - Operating Profit


Verastem reported $-18.28M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alaunos Therapeutics USD -1.19M 432K Sep/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Curis USD -12.51M 40K Jun/2024
Cytokinetics USD -178.37M 11.61M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Laboratory Of America USD 382M 15.3M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -18.28M 9.78M Jun/2024